With the caveat that I am not privvy to all the clinical findings thus far, I like this move to cut UCB-791. With phase I data in hand for their fully human VEGFR2 antibody, and full ownership of the product, and phase II data in hand for the UCB antibody, IMCL presumably has clinical information to determine the best development candidate going forward.
I also like the implication from the PR that once phase I studies are completed in 1H07, an aggressive phase II development program on anti-VEGFR2 will be implemented. Full ownership. Huge market potential. Fully human. Signs of efficacy in phase I. Strong intellectual property position. Gotta like it. Will be interesting to learn about their development strategy going forward - what tumor types? pairing with what chemos? with what biologicals? trial structures and endpoints? strategy for differentiation from Avastin primarily on basis of efficacy, safety, or both?
Market Data 
Markets 
AI
